Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study

Author(s): Lotte M. Knapen, Suzanne T.A.M. Dittrich, Frank de Vries, Jakob Starup-Linde, Peter Vestergaard, Ronald M.A. Henry, Leo M.L. Stolk, Cees Neef, Marloes T. Bazelier

Journal Name: Current Drug Safety

Volume 8 , Issue 5 , 2013

Become EABM
Become Reviewer
Call for Editor


Observational studies have shown conflicting results on the potential protecting effect of biguanide use with the risk of colorectal neoplasms. In addition, the cellular mechanism can either support or oppose biguanides influence on colorectal carcinoma. Our objective was to evaluate the association between biguanide use and colorectal carcinoma. A population-based cohort study using healthcare data from the Danish National database (1996-2007), was conducted. Oral antidiabetic drug users (n = 177,281) were matched 1:3 with a population-based reference group. Cox proportional hazard models estimated hazard ratios (HRs) of colorectal carcinoma. Stratification was performed to analyse the risk of colorectal cancer in current biguanide users. Two sub-analyses were performed, to investigate the risk of colorectal cancer associated with discontinuous and prolonged use of biguanides.

Instead of a protective effect, we found that current biguanide users had a 1.2-fold increased risk of colorectal cancer (HR = 1.19, 95% CI = 1.08-1.30) as compared with the non-diabetes reference group. Prolonged use was not inversely associated with colorectal cancer either. When studying colorectal risk with biguanides, the underlying T2DM should be taken into account since a 1.3-1.6-fold increased risk was found in oral antidiabetic drug users compared to controls unexposed to diabetic medication. This study could not detect a protective effect of biguanide use with colorectal cancer. Therefore, this study does not support a further investigation of the effectiveness of biguanides to prevent colorectal carcinoma in clinical studies.

Keywords: Biguanide, colorectal neoplasms, diabetes mellitus type two (T2DM), malignancies, metformin, pharmacoepidemiology.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 20 December, 2013
Page: [349 - 356]
Pages: 8
DOI: 10.2174/15680266113136660068
Price: $65

Article Metrics

PDF: 37